Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This program helped us drive renewed efficiencies and strengthen our supply chain |
| So nice one, two combo record quarter for TEG |
| We've demonstrated the safety and the reliability and the performance of that system, 9% to 12% yield enhancement on average |
| We're not going to talk about specific pricing given the competitive environment, but we remain committed to growing share and improving our margins as a result of technological advancements that have unrivaled value propositions |
| Margin expansion through FY2024 foreshadows the compounding impact of changes in volume and mix, coupled with productivity and operating leverage |
| We are proud of our accomplishments and enthusiastic about the many opportunities to grow our business moving forward |
| Through portfolio evolution, operational excellence and resource allocation, we've strengthened our leadership in plasma while building our high-growth, high-margin hospital segment to expand our scale and leverage |
| The fundamental aspects of our plans are continued market leadership, strengthened market leadership in plasma |
| continued to be favorable and disposables – with disposables growing 7% in the quarter and 17% year-to-date |
| With robust recovery continuing, our operational excellence program helped us ensure delivery for our customers as they continue to collect historically high volumes, further highlighting the need for reliability, donor safety, and yield-enhancing solutions |
| And the [indiscernible], the Apheresis, the collaboration has been really excellent |
| The rollout of Persona, our proprietary technology proven to increase yield 9% to 12% on average, continues to gain momentum with more than 25 million collections |
| The limited market release of our new Express Plus Technology has been encouraging |
| So that bodes well for the future growth |
| And so, we're quite optimistic about what we can do together to advance that product |
| The highest growth that we are experiencing is actually from our customers who were the adopters of Persona because of the yield benefits as well as the gain in productivity from the integrated system |
| We remain bullish on plasma longer term, and we are confident in our ability to maintain leading market share while continuing to migrate customers to our latest technology |
| Both in the quarter and year-to-date, we continue to benefit from increasing Blood Center plasma collections, particularly within newly established plasma centers in Egypt, and strong efforts to increase the collection of red cell units in the U.S |
| And that bodes extremely well for the future because we see hospitals embracing the technology, scaling the technology, adding additional tags to their arsenal |
| The portfolio and manufacturing network rationalization initiatives we introduced in November are critical for preserving Blood Center's ability to generate strong EBITDA as we continue to work with our customers to migrate them to alternative products |
| Again, we see robust growth across the board |
| Our Hospital business had an especially strong third quarter with revenue growth of 22% as all of our products grew double digits |
| Year-to-date Hospital grew 17% driven by the continued success of Vascular Closure and hemostasis management |
| In interventional technologies, which includes Vascular Closure and OpSens products, Vascular Closure grew 28% in the third quarter and 29% year-to-date, driven by continued momentum with new account openings and improving utilization throughout the U.S |
| This footprint will also provide the foundation for future growth, particularly as we realize opportunities through our innovation and M&A pipelines |
| Internationally, our products are gaining recognition, contributing approximately 200 basis points of growth in the third quarter |
| This is an exciting milestone for us as we continue to expand our Hospital business with procedure enabling technologies in high growth areas |
| What we really like – this is true in Europe and it's especially true in Japan and we were able to secure a very favorable reimbursement in Japan to reflect this |
| And we have exceptionally good data in support of that |
| And so we think it's an outstanding fit for markets that are looking for a better answer on closure, but want to put a premium on safety and productivity and patient satisfaction, all of which come with the Vascular Closure pipeline |
| Statement |
|---|
| Whole blood revenue declined 6% in the quarter and 9% year-to-date, predominantly driven by lower volumes associated with our decision to rationalize parts of this business, partially offset by benefits from last time buys |
| Blood Center revenue declined 3% in the third quarter and 1% year-to-date |
| That's an answer for all of our collectors in this environment to their productivity challenges |
| On the cash flow side, there were some collection delays that I mentioned earlier that has mostly resolved itself, and it really was more of a timing issue around year end with certain collections |
| A good chunk of that is economic, obviously for the donor demographic they're still struggling quite heavily in this marketplace, unfortunately for them |
| The combination of the adjusted interest expense, fluctuations in FX and adjusted income tax had about a $0.09 unfavorable impact in the third quarter and about $0.02 unfavorable impact year-to-date when compared with the prior year |
| We are watching the events unfolding in the Red Sea that has created some additional cost |
| But in our case, coming off of a relatively modest performance, particularly this time last year |
| Apheresis revenue was down 1% in the quarter, but grew 2% year-to-date |
| But secondly, we need to continue our operational excellence initiatives that you've heard us talk so much about here over the prior couple of years |
| In our third quarter, cash outflow from operating activities was $0.5 million, and free cash outflow before restructuring and restructuring-related costs was $20.3 million, primarily due to the timing of disbursements, collection delays, which temporarily increased accounts receivable and increased inventory balances |
| The rates have certainly come back down from their peaks back a year or so ago |
| Are we back on the upswing? Any signs of kind of stabilization there? It's been sort of noisy through the pandemic, but had felt like we had gotten a little bit more normal |
| Obviously, that doesn't happen if we don't continue to drive utilization |
| And again, we don't see any abatement there |
| We have to get to the high 20s, and we want to make – I don't want to get too far ahead of our guidance that's going to come out in May, but we have to make a meaningful step next year or we're not going to hit it, right |
| And then we had some turnover on our staff, which led to a bit of an uptick |
| So that will hopefully drop down to the bottom line |
Please consider a small donation if you think this website provides you with relevant information